Previous Page Next Page

Clinical Data

Larotrectinib efficacy and safety have been evaluated in three clinical trials in patients with cancers with NTRK gene fusion [1-3]. Patients were to have unresectable or metastatic solid tumours progressing following systemic therapy or requiring surgery with substantial morbidity for locally-advanced disease [1, 2].

Patients were prospectively identified as carrying the NTRK gene fusion, detected by molecular profiling as routinely performed at each site, and consecutively enrolled into one of three open-label, single-arm protocols [1, 2]:

  • A phase 1 study in adults (LOXO-TRK-14001; NCT02122913) [4];
  • A phase 1/2 study in children (SCOUT; NCT02637687); and
  • A phase 2 “basket” study in adolescents and adults (NAVIGATE; NCT02576431).

Click on the following links to learn more about the currently available efficacy and safety outcomes from these trials.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings